Media release Ypsomed and MTD complete the sale of the pen needle and BGM business Burgdorf, 02.08.2024, 7.00 a.m. – Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have completed the sale of the pen needle and blood glucose monitoring (BGM) systems business. This transaction marks a pivotal moment for Ypsomed, as it allows the company to focus its diabetes care business on commercialisation and development of its innovative mylife Loop insulin pump solution. 
The sale of the pen needle and BGM business between Ypsomed and MTD was announced on 27 March 2024. The transaction is now legally completed, having fulfilled all conditions set out in the contract. "At Ypsomed Diabetes Care, we fully concentrate on innovative insulin pump solutions," states Sébastien Delarive, Chief Business Officer Diabetes Care of the Ypsomed group. "The completion of this acquisition is a transformative milestone for MTD Group," says Charles Bouaziz, CEO of MTD. "It accelerates our growth, opens new strategic markets, and expands our product portfolio, establishing us as the second-largest producer of pen needles worldwide." Step-by-step transition During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The vacant space will be used for new tool making facilities at the Solothurn site. | 
